title: CD8 expression on B cells in chronic lymphocytic leukemia: a case report and review of the literature.
abstract: The expression of CD8, a restricted T-cell antigen, on B cells in B chronic lymphocytic leukemia is rare, and its significance, if any, remains unknown. We report herein a patient with B chronic lymphocytic leukemia in whom CD8 was strongly expressed on all B cells, both in the bone marrow and peripheral blood. The patient required no therapy for 6 years after being diagnosed as having B chronic lymphocytic leukemia. Then, when the disease progressed, he was treated with conventional doses of fludarabine phosphate (25 mg/m(2) daily for 5 days), but unlike other patients with B chronic lymphocytic leukemia he tolerated this therapy poorly. He received a total of only 4 series of fludarabine therapy, and following each course of treatment, he developed considerable myelosuppression. After the fourth course of therapy, his bone marrow failed to show any evidence of regeneration, and he died as a result of intercurrent respiratory tract infection 1 month after his last dose of fludarabine was given.
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, State University of New York at Buffalo. aislam@acsu.buffalo.edu
authors.forename: A
authors.initials: A
authors.lastname: Islam
authors.forename: A O
authors.initials: AO
authors.lastname: Vladutiu
authors.forename: T
authors.initials: T
authors.lastname: Donahue
authors.forename: S
authors.initials: S
authors.lastname: Akhter
authors.forename: A M
authors.initials: AM
authors.lastname: Sands
authors.forename: J L
authors.initials: JL
authors.lastname: Ambrus
mesh_terms: D018941:Antigens, CD19 / Q000032:analysis; D018951:Antigens, CD20 / Q000032:analysis; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000276:immunology*; D001854:Bone Marrow Cells / Q000276:immunology; D018956:CD5 Antigens / Q000032:analysis; D016827:CD8 Antigens / Q000032:analysis*; D017809:Fatal Outcome; D005434:Flow Cytometry; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D017455:Receptors, IgE / Q000032:analysis; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D018941:Antigens, CD19; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D018956:CD5 Antigens; D016827:CD8 Antigens; D017455:Receptors, IgE; D014740:Vidarabine; C024352:fludarabine